MedTrace Logo

Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

NCT05405894 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-05-14

No results posted yet for this study

Summary

This two-year observational, open-label clinical trial will evaluate the efficacy of a once-yearly infusion of zoledronic acid after denosumab discontinuation to maintain tissue mineral density and bone microarchitecture using high-resolution peripheral quantitative computed tomography (HR-pQCT) among post-menopausal women with osteoporosis.

Conditions

  • Osteoporosis
  • Osteoporosis, Postmenopausal
  • Osteopenia
  • Bone Loss

Interventions

DRUG

Zoledronic acid

Once-yearly infusion of zoledronic acid following denosumab discontinuation

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • William Brent Edwards, PhD · University of Calgary

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-07-01
Completion
2025-07-01
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05405894 on ClinicalTrials.gov